ReviewPharmaceuticals (Basel, Switzerland)2025

Minimal Residual Disease Significance in Multiple Myeloma Patients Treated with Anti-CD38 Monoclonal Antibodies.

Federico Caroni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.